REA
A multifusion protein-based vaccine formulated with MPL/DDA.
Read MoreNETB-EA
The Khader Lab in collaboration with EclipTB Inc andBlueWillow Biologics Inc., have developed an intranasal booster sub-unit, mucosal vaccine comprising of Mtb immunodominant antigens Early secreted antigenic target 6 kDa andAntigen 85B together with nanoemulsion adjuvant NE01-NETB-EA.
Read MorepcDNA3.1-rpfB, pcDNA3.1-rpfD
The candidate vaccine we are developing is a recombinant plasmid DNA vaccine. Two genes from the rpfs family, namely rpfB and rpfD, were inserted full-length into the pcDNA3.1 plasmid along with the Kozak sequence, resulting in recombinant plasmids pcDNA3.1-rpfB and pcDNA3.1-rpfD. The vaccination method used on test animals is intramuscular injection of the recombinant plasmid…
Read MoreAd5-105K
The Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) developed by CanSino Biologics Inc. is a non-replicating viral-vectored vaccine intended for administration via nebulized inhalation by mouth. It is designed to induce both local mucosal immunity in the respiratory tract and systemic immune responses against Mycobacterium tuberculosis (Mtb). The adenovirus type 5 (Ad5) backbone functions as…
Read MoreBCG-STING
BCG-STING is a recombinant BCG strain that overexpresses the small molecule STING agonist cyclic di-AMP. For prevention of Mtb proliferation BCG-STING is more potent than standard BCG in mouse, guinea pig, and NHP models, and it is also safer than BCG-WT in mouse models. BCG-STING can be produced by fermentation, overcoming current BCG production limitations.
Read More